Lantheus Holdings announces acceptance and priority review of new drug application for PyLTM (18F DCFPyL), a PSMA targeted prostate cancer PET imaging agent

Lantheus

9 December 2020 - PDUFA action date of 28 May 2021 assigned by U.S. FDA.

Lantheus Holdings and Progenics Pharmaceuticals today announced that the U.S. FDA has accepted the new drug application for PyLTM (18F DCFPyL), a prostate specific membrane antigen (PSMA) targeted positron emission tomography imaging agent for prostate cancer.

Read Lantheus press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , US , Dossier , Diagnostic agent